Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study)
Response to: comment on "validation and predictive capacity of a dutch version of the FLARE-RA questionnaire within the context of a TNFi-tapering trial".
Initial glucocorticoid bridging in rheumatoid arthritis: does it affect glucocorticoid use over time?